

[REDACTED]
[REDACTED]
[REDACTED]

Donneybrook Medical Centre
Clarendon Street
Hyde
Cheshire
SK14 2AH
Tel: 0161 368 3838
Email: gmicb-tameside.donneybrook@nhs.net

21st July 2022

HM Coroner's Office
1 Mount Tabor Street
Stockport
SK1 3AG

Dear Sirs

Re: Death of Amanda Carole Hesketh

Thank you for your Regulation 28: Report to Prevent Future Deaths dated 22nd October 2021 following the inquest into the very sad death of Amanda Carole Hesketh. You concluded her cause of death was as a consequence of complications of her pain relief medication. You also highlighted your concerns that a death of this type could occur again without further action from Donneybrook Medical Centre.

Donneybrook Medical Centre and I take the health and safety of our residents very seriously and I very much share your desire to prevent any such recurrence. I am grateful to you for bringing your findings to my attention and I set out below the steps that have taken place, and will be taking place, on the issues you raise.

1. We have utilised the help from of the Medicines Optimisation Team at the GMICB (previously CCG) to assist, categorise and prioritise patients receiving repeat prescriptions of multiple analgesics.
2. A search was undertaken looking at patients on multiple analgesia, to identify who had already been reviewed and who had not.
3. From the searches these patients were categorised into categories or risk and urgency:
Red – Urgent, this would include no reviews on multiple analgesia including schedule 2 controlled drugs (Morphine, Fentanyl or Oxycodone).
Amber - This would include no reviews on multiple analgesia including pentinoids, Gabapentin or Pregabalin.
Green – This would include no review on multiple analgesia to include paracetamol, codeine and Nsaids.
4. In additional, all patients identified in the search who have already had a review within the last 12 months will be checked, quality of the review and any instructions or call backs noted. If necessary they will be added into the Red/Amber/Green urgency categories for a

further review. The date for their next review will be added to the diary in line with recommendations.

5. Once the searches had been completed and patient groups identified a clinical meeting was held with a presentation of patients on the red priority list and a plan has been put in place to review these patients.
6. The red priority patients are in the process of being reviewed, the target for the red priority list is for it to be completed by the end of August 2022.
7. A plan has been put in place to introduce a limitation on how many months prescriptions can be given before a patient's next review; this is 3 months in the red priority, 6 months in the amber priority and 12 months in the green. Once a review is due the prescription clerk will highlight this then an appointment will be automatically made with the GP for further review.
8. Safety netting has been put in place to ensure the various risk groups will always be reviewed going forward - collating each patient's last review date and their next review date. Searches will be run every month to identify any new patients who will need adding to this group
9. The practice will recruit a pharmacist who will support this work and while the recruitment is ongoing locum agency staff will be employed.
10. Patients on the amber list are currently being reviewed with the green list will be reviewed by in-house pharmacist provision.

I hope that we have provided you with the necessary assurances, with these medicines management changes, in relation to your concerns.

Please contact me if you require any further information or if I can assist further in any way.

Kind Regards

A black rectangular redaction box covering the signature of the sender.

Operations Manager